Joeky Senders

63 Venous thromboembolism en intracranial hemorrhage References 1. Fadul C WJ, Thaler H, Galicich J, Patterson Jr RH, Posner JB. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology. 1988;38:1374-1379. 2. Marcus LP, McCutcheon BA, Noorbakhsh A, et al. Incidence and predictors of 30-day readmission for patients discharged home after craniotomy for malignant supratentorial tumors in California (1995-2010). Journal of neurosurgery. 2014;120(5):1201-1211. 3. Missios S KP, Nanda A, Bekelis K. Craniotomy for glioma resection: a predictivemodel. World neurosurgery. 2015;83(6):957-964. 4. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high- grade glioma. Neuro Oncol. 2007;9(2):89-95. 5. Streiff MB, Ye X, Kickler TS, et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. Journal of neuro-oncology. 2015;124(2):299-305. 6. Smith TR, Lall RR, Graham RB, et al. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. Journal of neuro-oncology. 2014;120(2):347- 352. 7. Khalil J, Bensaid B, Elkacemi H, et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol. 2015;13:204. 8. Sartori MT, Della Puppa A, Ballin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol. 2011;104(1):225-231. 9. Cote DJ ST. Venous thromboembolism in brain tumor patients. Journal of Clinical Neuroscience. 2016;25:13-18. 10. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. The American journal of medicine. 2006;119(1):60-68. 11. Kimmell KT WK. Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease. Journal of Neuro-oncology. 2014;120(3):567-573. 12. Edwin NCK, M. N.; Sohal, D.; McCrae, K. R.; Ahluwalia, M. S.; Khorana, A. A. Recurrent venous thromboembolism in glioblastoma. Thrombosis research. 2016;137:184-188. 13. Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery. 2003;98(6):1175-1181. 14. Perry SL, Bohlin C, ReardonDA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. Journal of neuro-oncology. 2009;95(1):129-134. 15. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of thrombosis and haemostasis : JTH. 2010;8(9):1959-1965. 16. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452-e466. 17. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of thrombosis and haemostasis : JTH. 2013;11(1):56-70.